Résumé LA CLINIQUE MAYO A SIGNALÉ que des cardiopathies monovalvulaires ou
multivalvulaires semblent faire leur apparition chez un groupe de 24 femmes de moins de …

Two appetite suppressants combined, called Fen-Phen (for fenfluramine and phentermine),
were effective for sustained weight control but were found to be associated with rare valvular …

Fenfluramine was approved in the United States in 1973 and also in Europe and was used
widely, albeit generally short-term, with no published reports of heart valve abnormalities …

The popular diet drugs, fenfluramine and dexfenfluramine, were withdrawn from the market
in the United States after the publication of an association of these drugs with valvulopathy …

The recently described cardiac valvulopathy attributed to the appetite-suppressant drugs
fenfluramine and phentermine (fen-phen)'took the medical community and the public by …

Appetite-suppressant drugs are categorised as those that act via the catecholamine
pathways (phentermine) or those that act via the serotonin pathways (fenfluramine …

Serotoninergic appetite-suppressant drugs, fenfluramine and dexfenfluramine, were
withdrawn from the market in September 1997 on account of two major cardiopulmonary …

Background: Phentermine–fenfluramine and dexfenfluramine use for weight loss has been
previously associated with increased prevalence of valvular heart disease. This association …

The association between valvular heart disease and diet pills was discovered several years
ago in a small cohort of patients. Subsequent uncontrolled surveys and reports suggested a …

Pharmacotherapy has become an increasing popular strategy for treatment of obesity in part
to avoid its associated morbid cardiac and cerebrovascular complications. The appetite …